COVID-19 Vaccine Dosing: Pharma Says Follow The Science As It Gathers Data
Executive Summary
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
You may also be interested in...
US Remains Conservative On Vaccine Dosing Regimens As CDC’s ACIP Highlights Minimal Comfort With Relying On Unproven Correlates
The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices concerns about making COVID-19 vaccine dose regimen changes based on unproven immune correlates of protection could be a warning sign to sponsors about roadblocks they might face if updating vaccines to address viral variants or conducting pediatric studies relying on such surrogate endpoints.
Biden Team To ‘Explore’ Dose-Sparing Strategies For COVID-19 Vaccines, But Details Sparse
New US leadership has a more comprehensive COVID-19 strategy, but that doesn’t mean all the plans are fully fleshed out yet. While Biden team declines to provide any details on what new vaccine dosing strategies they plan to examine, CDC quietly updates its recommendations to allow six weeks between shots.
UK Begins Controversial 12 Week Strategy With AZ and Pfizer Vaccines
Entering a new lockdown, the UK sees its plans to space out doses of the COVID-19 vaccines to 12 weeks as crucial to overcoming the pandemic.